Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics, Inc.verified

PLX

Price:

$1.75

Market Cap:

$140.74M

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis...[Read more]

Industry

Biotechnology

IPO Date

1998-05-15

Stock Exchange

AMEX

Ticker

PLX

The Enterprise Value as of December 2025 (TTM) for Protalix BioTherapeutics, Inc. (PLX) is 135.27M

According to Protalix BioTherapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 135.27M. This represents a change of -6.77% compared to the average of 145.09M of the last 4 quarters.

Protalix BioTherapeutics, Inc. (PLX) Historical Enterprise Value (quarterly & annually)

How has PLX Enterprise Value performed in the past?

The mean historical Enterprise Value of Protalix BioTherapeutics, Inc. over the last ten years is 217.70M. The current 135.27M Enterprise Value has changed 6.11% with respect to the historical average. Over the past ten years (40 quarters), PLX's Enterprise Value was at its highest in in the March 2016 quarter at 843.65M. The Enterprise Value was at its lowest in in the December 2021 quarter at 32.14M.

Quarterly (TTM)
Annual

Average

217.70M

Median

106.96M

Minimum

31.20M

Maximum

963.93M

Protalix BioTherapeutics, Inc. (PLX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Protalix BioTherapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 165.32%

Maximum Annual Enterprise Value = 963.93M

Minimum Annual Increase = -81.16%

Minimum Annual Enterprise Value = 31.20M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2024122.12M-1.69%
2023124.23M50.09%
202282.77M165.32%
202131.20M-79.47%
2020151.94M65.51%
201991.80M64.17%
201855.92M-36.24%
201787.70M-81.16%
2016465.41M-51.72%
2015963.93M-44.02%

Protalix BioTherapeutics, Inc. (PLX) Average Enterprise Value

How has PLX Enterprise Value performed in the past?

The current Enterprise Value of Protalix BioTherapeutics, Inc. (PLX) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

3-year avg

109.71M

5-year avg

102.45M

10-year avg

217.70M

Protalix BioTherapeutics, Inc. (PLX) Enterprise Value vs. Peers

How is PLX’s Enterprise Value compared to its peers?

Protalix BioTherapeutics, Inc.’s Enterprise Value is less than SELLAS Life Sciences Group, Inc. (158.74M), greater than Coherus Oncology, Inc. (41.17M), less than Invivyd, Inc. (212.37M), less than Protara Therapeutics, Inc. (237.55M), less than Genfit S.A. (256.38M), less than Codexis, Inc. (193.41M), less than OmniAb, Inc. (204.55M), less than NEONC TECHNOLOGIES HOLDINGS, INC. (180.95M), less than MediWound Ltd. (170.94M), less than Sangamo Therapeutics, Inc. (163.49M),

CompanyEnterprise ValueMarket cap
158.74M$183.40M
41.17M$142.57M
212.37M$294.66M
237.55M$265.09M
256.38M$290.81M
193.41M$150.14M
204.55M$212.02M
180.95M$182.08M
170.94M$195.31M
163.49M$178.38M

Build a custom stock screener for Protalix BioTherapeutics, Inc. (PLX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Protalix BioTherapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Protalix BioTherapeutics, Inc. (PLX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Protalix BioTherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Protalix BioTherapeutics, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Protalix BioTherapeutics, Inc. (PLX)?

What is the 3-year average Enterprise Value for Protalix BioTherapeutics, Inc. (PLX)?

What is the 5-year average Enterprise Value for Protalix BioTherapeutics, Inc. (PLX)?

How does the current Enterprise Value for Protalix BioTherapeutics, Inc. (PLX) compare to its historical average?